Abstract
The basic principle of allergen specific immunotherapy conducted by subcutaneous injection is the administration of increasing doses of allergen up to a maintenance dose or a maximum tolerated dose to ameliorate IgE antibody mediated allergic inflammation and associated symptoms, and reduce the need for symptomatic medication. The magnitude of the dose is apparently important in ensuring the success of treatment. Whereas low allergen doses favor a Th2 cytokine response and a switch to IgE, high allergen doses favor induction of regulatory T-cells and modification or down-regulation of the Th2 phenotype [1]. However the administration of high doses in man carries an increased risk for the induction of undesirable side-effects, and at worst life-threatening anaphylactic reactions which are a logical risk with a causal treatment.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Larche M, Akdis CA, Valenta R (2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6:761–71
Maasch HJ, Marsh DG (1987) Standardized extracts: Modified allergens — Allergoids. Clin Rev Allergy 5:89–106
Akdis CA, Blaser K (2001) Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 22:175–8
Cirkovic TD, Bukilica MN, Gavrovic MD et al (1999) Physicochemical and immunologic characterization of low molecular- weight allergoids of Dactylis glomerata pollen proteins. Allergy 54:128–34
Mistrello G, Brenna O, Roncarolo D et al (1996) Monomeric chemically modified allergens: Immunologic and physicochemical characterization. Allergy 51:8–15
Rappuoli R, Douce G, Dougan G, et al (1995) Genetic detoxification of bacterial toxins: a new approach to vaccine development. [Review]. Int Arch Allergy Immunol 108:327–33
Spangfort MD, Mirza O, Ipsen H, et al (2003) Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed muta-genesis. J Immunol 171:3084–90
Breiteneder H, Mills EN (2005) Molecular properties of food allergens. J Allergy Clin Immunol 115:14–23
Stadler MB, Stadler BM (2003) Allergenicity prediction by protein sequence. FASEB J 17:1141–3
Furmonaviciene R, Sewell HF, Shakib F (2000) Comparative molecular modelling identifies a common putative IgE epitope on cysteine protease allergens of diverse sources. Clin Exp Allergy 30:1307–13
Arquint O, Helbling A, Crameri R, et al (1999) Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J Allergy Clin Immunol 104:1239–43
Ferreira F, Ebner C, Kramer B, et al (1998) Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy. FASEB J 12:231–42
Holm J, Gajhede M, Ferreras M (2004) Allergy vaccine engineering: Epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 173:5258–67
Rabjohn P, West CM, Connaughton C (2002) Modification of peanut allergen Ara h 3: Effects on IgE binding and T cell stimulation. Int Arch Allergy Immunol 128:15–23
Swoboda I, Bugajska-Schretter A, et al (2007) A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 178:6290–6
Haselden BM, Kay AB, Larche M (1999) Immunoglobulin E-independent major histocom-patibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189:1885–94
Kay AB, Larche M (2004) Allergen immunotherapy with cat allergen peptides. Springer Semin Immunopathol 25:391–9
Verhoef A, Alexander C, Kay AB, et al (2005) T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2:e78
Vrtala S, Hirtenlehner K, Vangelista L (1997) Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments – Candidates for a novel form of specific immunotherapy. J Clin Invest 99:1673–81
van Hage-Hamsten M, Kronqvist M, Zetterström O (1999) Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104:969–77
Vrtala S, Focke M, Sperr W, et al (2001) Recombinant hypoallergenic fragments of the major Timothy grass pollen allergen, Phl p 6, for immunotherapy. J Allergy Clin Immunol 107:S257
Kinnunen T, Buhot C, Narvanen A (2003) The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Eur J Immunol 33:1717–26
Kinnunen T, Jutila K, Kwok WW, et al (2007) Potential of an altered peptide ligand of lipoc-alin allergen Bos d 2 for peptide immunotherapy. J Allergy Clin Immunol 119:965–72
Linhart B, Valenta R (2004) Vaccine Engineering Improved by Hybrid Technology. Int Arch Allergy Immunol 134:324–31
Hirahara K, Tatsuta T, Takatori T, et al (2001). Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 108:94–100
Karamloo F, Schmid-Grendelmeier P, Kussebi F (2005) Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 35:3268–76
Punnonen J (2000) Molecular breeding of allergy vaccines and antiallergic cytokines. Int Arch Allergy Immunol 121:173–82
Ferreira F, Wallner M, Breiteneder H et al (2002) Genetic engineering of allergens: Future therapeutic products. Int Arch Allergy Immunol 128:171–8
Gafvelin G, Parmley S, Neimert-Andersson T, et al (2007) Hypoallergens for allergen-specific immunotherapy by directed molecular evolution of mite group 2 allergens. J Biol Chem 282:3778–87
Wild C, Wallner M, Hufnagl K, et al (2007) A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62:33–41
Vrtala S, Hirtenlehner K, Susani M et al (2001) Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB J 15:2045–7
Pauli G, Purohit A, Oster JP, et al (2000) Comparison of genetically engineered hypoaller-genic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: Results obtained in a French population. Clin Exp Allergy 30:1076–84
Kahlert H, Weber B, Cromwell O, et al (2003) Evaluation of the allergenicity of hypoaller-genic recombinant derivatives of Bet v 1 using basophil activation by CD203c expression measurement. In: Marone G, editor. Clinical Immunology and Allergy in Medicine. Naples, Italy: JGC Editions, 735–40
Niederberger V, Horak F, Vrtala S, et al (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101(Suppl 2):14677–82
Reese G, Ballmer-Weber BK, Wangorsch A, et al (2007) Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: Destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines. J Allergy Clin Immunol 119:944–51
Linhart B, Hartl A, Jahn-Schmid B, et al (2005) A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 115:1010–6
Ma Y, Gadermaier G, Bohle B et al (2006) Mutational analysis of amino acid positions crucial for IgE-binding epitopes of the major apple (Malus domestica) allergen, Mal d 1. Int Arch Allergy Immunol 139:53–62
Son DY, Scheurer S, Hoffmann A, et al (1999) Pollen-related food allergy: Cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen. Eur J Nutr 38:201–15
Westritschnig K, Focke M, Verdino P, et al (2004) Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 172:5684–92
Smith AM, Chapman MD (1996) Reduction in IgE binding to allergen variants generated by site- directed mutagenesis: Contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 33:399–405
Takai T, Yokota T, Yasue M, et al (1997) Engineering of the major house dust mite allergen Der f2 for allergen-specific immunotherapy. Nat Biotechnol 15:754–8
Olsson S, van Hage-Hamsten M, Whitley P (1998) Contribution of disulphide bonds to anti-genicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol Immunol 35:1017–23
Bonura A, Amoroso S, Locorotondo G, et al (2001) Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: A member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 126:32–40
Drew AC, Eusebius NP, Kenins L, et al (2004) Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 173:5872–9
Korematsu S, Tanaka Y, Hosoi S, et al (2000) C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J Immunol 165:2895–902
Kauppinen J, Zeiler T, Rautiainen J, et al (1999) Mutant derivatives of the main respiratory allergen of cow are less allergenic than the intact molecule. Clin Exp Allergy 29:989–96
Takai T, Ichikawa S, Yokota T, et al (2000) Unlocking the allergenic structure of the major house dust mite allergen der f 2 by elimination of key intramolecular interactions. FEBS Lett 484:102–7
Swoboda I, de Weerd N, Bhalla PL, et al (2002) Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: Candidates for grass pollen-specific immuno-therapy. Eur J Immunol 32:270–80
Schramm G, Kahlert H, Suck R, et al (1999) “Allergen engineering”: Variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 162:2406–14
Wald M, Kahlert H, Weber B, et al (2007) Generation of a low Immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a. Clin Exp Allergy 37:441–50
Marazuela EG, Rodriguez R, Barber D, et al (2007) Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin Exp Allergy 37:251–60
Garcia-Ortega L, Lacadena J, Villalba M, et al (2005) Production and characterization of a noncytotoxic deletion variant of the Aspergillus fumigatus allergen Aspf1 displaying reduced IgE binding. FEBS J 272:2536–44
Reisinger J, Horak F, Pauli G, et al (2005) Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 116:347–54
Gafvelin G, Thunberg S, Kronqvist M, et al (2005) Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138:59–66
Weber B, Slamal H, Suck R (2003) Size exclusion chromatography as a tool for quality control of recombinant allergens and hypoallergenic variants. J Biochem Biophys Methods 56:219–32
Kettner J, Meyer H, Cromwell O, et al (2007) Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV results of 2 years of treatment (Phase II trial). Allergy 62(Suppl 83):262
Kettner J, Meyer H, Narkus A, et al (2007) Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious — results of a Phase III study. Allergy 62(Suppl 83):33
Tighe H, Takabayashi K, Schwartz D, et al (2000) Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allerge-nicity. J Allergy Clin Immunol 106:124–34
Crameri R, Fluckiger S, Daigle I, et al (2007) Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 62:197–206
Zhu D, Kepley CL, Zhang M, et al (2002) A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 8:518–21
Zhu D, Kepley CL, Zhang K, et al (2005) A chimeric human—cat fusion protein blocks cat-induced allergy. Nat Med 11:446–9
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer
About this chapter
Cite this chapter
Cromwell, O. (2010). Engineering Allergy Vaccines: Approaches Towards Engineered Allergy Vaccines. In: Pawankar, R., Holgate, S.T., Rosenwasser, L.J. (eds) Allergy Frontiers: Future Perspectives. Allergy Frontiers, vol 6. Springer, Tokyo. https://doi.org/10.1007/978-4-431-99365-0_3
Download citation
DOI: https://doi.org/10.1007/978-4-431-99365-0_3
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-99364-3
Online ISBN: 978-4-431-99365-0
eBook Packages: MedicineMedicine (R0)